Retrieve available abstracts of 16 articles: HTML format
Single Articles
August 2025
OGUNTALA JO, Yan AT Toward Evidence-Based Transfusion for Anemia in Acute Myocardial Infarction:
Still an Unfinished Story.
Ann Intern Med. 2025 Aug 19. doi: 10.7326/ANNALS-25-02486. PubMed
July 2025
ABRAMOV D, Van Spall HGC In HF with iron deficiency, IV ferric carboxymaltose did not reduce a composite
of first HF hospitalization or CV death at a median 17 mo.
Ann Intern Med. 2025;178:JC82. PubMedAbstract available
March 2025
OGUNTALA JO, Yan AT In acute MI and acute or chronic anemia, liberal vs. restrictive transfusion did
not affect recurrent MI or death.
Ann Intern Med. 2025 Mar 4. doi: 10.7326/ANNALS-25-00161. PubMedAbstract available
November 2024
MALIK A, Martin GS In adults with TBI and anemia, liberal vs. restrictive RBC transfusion did not
reduce unfavorable neurologic outcomes by 10% at 6 mo.
Ann Intern Med. 2024 Nov 5. doi: 10.7326/ANNALS-24-02456. PubMedAbstract available
October 2024
PORTELA GT, Carson JL, Swanson SA, Alexander JH, et al Effect of Four Hemoglobin Transfusion Threshold Strategies in Patients With Acute
Myocardial Infarction and Anemia : A Target Trial Emulation Using MINT Trial
Data.
Ann Intern Med. 2024 Oct 1. doi: 10.7326/M24-0571. PubMedAbstract available
June 2024
FLYNN DJ, Feuerstein JD In transfusion-dependent, angiodysplasia-related anemia, adding octreotide to
usual care reduced transfusions at 1 y.
Ann Intern Med. 2024 Jun 4. doi: 10.7326/ANNALS-24-00517. PubMedAbstract available
May 2024
WEITZ HH, Merli GJ, Carson JL Web Exclusive. Annals Consult Guys - Acute Coronary Syndrome and Anemia: When to
Transfuse?
Ann Intern Med. 2024;177:eW240002. PubMed
March 2024
MUKHERJEE D In acute MI and anemia, restrictive vs. liberal transfusion did not differ for a
composite of recurrent MI or death at 30 d.
Ann Intern Med. 2024 Mar 5. doi: 10.7326/J24-0010. PubMedAbstract available
February 2024
BASU A, Winn AN, Johnson KM, Jiao B, et al Gene Therapy Versus Common Care for Eligible Individuals With Sickle Cell Disease
in the United States : A Cost-Effectiveness Analysis.
Ann Intern Med. 2024;177:155-164. PubMedAbstract available
January 2024
WESEVICH A, Peek ME, Ratain MJ An Ethical and Financial Obligation for Sickle Cell Disease Gene Therapy in the
United States.
Ann Intern Med. 2024;177:85-86. PubMed
October 2023
CARLIN S, Eikelboom JW In healthy older adults, low-dose aspirin increased incident anemia at a median
4.7 y.
Ann Intern Med. 2023 Oct 3. doi: 10.7326/J23-0075. PubMedAbstract available
September 2023
CENTOR RM, McQuilten ZK Web Exclusive. Annals On Call - Low-Dose Aspirin and Iron Deficiency Anemia.
Ann Intern Med. 2023;176:eA220018. PubMed
July 2023
Correction: Effect of Low-Dose Aspirin Versus Placebo on Incidence of Anemia in
the Elderly.
Ann Intern Med. 2023 Jul 25. doi: 10.7326/L23-0274. PubMed
June 2023
MCQUILTEN ZK, Thao LTP, Pasricha SR, Artz AS, et al Effect of Low-Dose Aspirin Versus Placebo on Incidence of Anemia in the Elderly :
A Secondary Analysis of the Aspirin in Reducing Events in the Elderly Trial.
Ann Intern Med. 2023 Jun 20. doi: 10.7326/M23-0675. PubMedAbstract available
GOSHUA G, Calhoun C, Ito S, James LP, et al Distributional Cost-Effectiveness of Equity-Enhancing Gene Therapy in Sickle Cell
Disease in the United States.
Ann Intern Med. 2023;176:779-787. PubMedAbstract available
April 2023
LERMAN JB, Newby LK In HF with iron deficiency, IV ferric derisomaltose was associated with lower
rates of HF hospitalization or CV death.
Ann Intern Med. 2023;176:JC40. PubMedAbstract available